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Clostridium difficile infections (CDI) are the first cause of healthcare associated diarrhea in both Europe
and the USA, causing between 15,000 and 30,000 deaths annually. Over the age of 65, antibiotic treat-
ments are the two main risk factors of developing CDI. Fecal microbiota transplantation has a major role
to play in managing these infections. Gut microbiota dysbiosis associated with CDI has been now com-
prehensively analyzed.
Elderly individuals, patients treated with antibiotics or proton pump inhibitors have a dramatically
decreased level of gut microbiota diversity as well as undergoing structural changes in taxa composition.
In addition to this decreased diversity, patients with CDI present an increase in species belonging to
Proteobacteria and a decrease in Clostridiales Incertae Sedis XI, and some commensal bacteria as
Ruminococcaceae, Lachnospiraceae or Bifidobacterium longum for patients with CDI, caused by the 027
ribotype. Fecal microbiota transplantation is followed by a reestablishment of diversity, an increase in
Firmicutes and Bacteroidetes and a decrease in Proteobacteria, Enterobacteriaceae and Streptoccaceae.
Most of the studies are performed using metagenomics and sometimes yield contradictory results.
Large studies, including culture dependent techniques and metagenomics using optimized extraction
protocols to limit biases should be designed in order to comprehensively highlight the gut microbiota
dysbiosis and consider specific microbiome-based therapeutic approaches.
 2016 Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
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Clostridium difficile infections are the first cause of health-care
associated diarrhea and have shown a dramatic increase in severity
and incidence over the past decade [1]. CDI mainly involves
patients over the age of 65 who are being treated with antibioticsfor another infection [1]. This infection causes a substantial mortal-
ity rate which is estimated at between 15,000 and 30,000 annual
deaths in the USA [1]. Prolonged hospital stays further add to sub-
stantial increases in health care costs which are estimated at three
billion US dollars per year in Western countries. The recent under-
standing of the pathogenesis of CDI highlights that in addition to
the hospital-acquired infections, approximately one third of the
cases of CDI had no link to hospital environments, as recently
Fig. 1. Number of publications referenced in pubmed regarding ‘‘gut microbiota and Clostridium difficile infections”, ‘‘fecal microbiota transplantation” and ‘‘Clostridium
difficile infections” from 2007 to July 2016.
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transmission study [2]. Infants represent another significant poten-
tial reservoir with up to 45% of infants carried C. difficile, including
13% carrying a toxigenic strain [3]. Managing CDI has long been
exclusively based on antibiotic treatment (metronidazole, van-
comycine or fidaxomicin), although this was associated with fre-
quent recurrences. Fecal microbiota transplantation (FMT), which
is already the reference for CDI recurrences, could be used in the
first instance for severe CD infections, including those caused by
the ribotype 027 [4–6].
Gut microbiota composition has been extensively explored,
notably since the advent of metagenomics tools [7]. Conse-
quently, relationships have been postulated between gut micro-
biota composition and a range of diseases such as obesity,
malnutrition or inflammatory bowel diseases [7]. Various studies
exploring the gut microbiota of patients who develop a CDI have
suggested that this composition plays a role in the likelihood of
developing CDI [8]. This has also been supported by the fact that
undisrupted microbiota can resist the colonization of pathogens
[9]. More recently, changes in gut composition over time after
fecal microbiota composition has also been explored. In this
paper, we propose a comprehensive review of this topic which
is of increasing interest in the literature (Fig. 1). In doing so, we
aim to present an overview of the relationships between gut
microbiota and CD infections. Before describing the gut micro-
biota changes associated with CDI and following FMT, we briefly
review the dysbiosis associated with the main risk factors of CDI
(see Fig. 2).Gut microbiota dysbiosis and antibiotics
The most commonly associated risk factor of developing a CDI
remains antibiotic use, as demonstrated by both clinical observa-
tions and murine-based studies [10,11]. Antibiotics result in both
short- and long-term changes in the composition of gut microbiota
[7]. One of the major consequences is a decrease in gut microbiota
diversity, regardless of the exploratory technique used (molecular
tools or culture-dependent approach) [11,12]. In addition, the
effect of antibiotics on gut microbiota may also be species-
specific [13]. Persistent effects have been described, particularly
following the use of quinolones. Although the reconstitution of
microbiota diversity is the rule once antibiotics have been stopped,
recovering the initial composition can sometimes be incomplete
[11,13,14]. All antibiotics can lead to a CDI but clindamycin, peni-
cillins and cephalosporins are the classes which are more fre-
quently associated with it. Of the most frequently changes
observed following the use of penicillins, we noted a decrease in
both gram positive anaerobic and aerobic cocci as well as a
decrease in enterobacteria. Cephalosporins, as well as large spec-
trum penicillins (such as amoxicillin/clavulanic and piperacillin/
tazobactam), have the same consequence of leading to a decrease
in clostridia, lactobacilli and bifidobacteria [7]. In terms of the clin-
damycin, in addition to a decrease in total anaerobic bacteria, a dis-
appearance or a dramatic decrease in Bifidobacterium, Clostridium
and some species in the Bacteroides genera was also observed [7].
Finally, it is important to underline that strong inter-individual dif-
ferences in gut microbiota composition have been observed among
Fig. 2. Gut microbiota changes depending of risk factors of C. difficile infections, during C. difficile infections and after fecal microbiota transplantation.
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infections [15].Gut microbiota dysbiosis and IPP
One of the other risk factors highlighted was individuals treated
with proton pump inhibitors (PPI). A recent metagenomics study
has compared the gut microbiota of 33 patients who had been
using PPI for more than 5 years with 29 controls. This revealed a
decrease in Bacteroidetes and an increase in Firmicutes at the
phylum level [16]. In addition, at the phylum level, Holdemania
filiformis increased while Pseudoflavonifractor capillosus [16]
decreased. Decreased diversity was observed, with an overrepre-
sentation of oral bacteria such as Rothia spp. in patients treated
with PPI [16], while in another study by Freedberg et al., no
changes in gut diversity were observed [17]. Finally, a significant
increase in Enterococcus, Streptococcus and Staphylococcus genera
as well as Escherichia coli was observed in a 1815 cohort analysis
including 211 participants using PPIs [18]. Interestingly, Freedberg
obtained similar results, with an increase in Enterococcaceae and
Streptococcaceae in PPI users developing a C. difficile infection, but
also a decrease in Clostridiales [17]. Finally, Jackson et al. also
observed decreased diversity but a higher abundance of Streptococ-
cus [19], which was previously suggested to be a risk factor for
developing CDI in mice [20].Gut microbiota dysbiosis and age
Being over the age of 65 is one of the main risk factors of devel-
oping a C. difficile infection. The composition of gut microbiota isdifferent to that of younger adults and varies dramatically between
elderly individuals [21]. A shift toward a predominance of Bac-
teroidetes [22] and Proteobacteria [23] phyla was observed in
elderly individuals in comparison with younger individuals. Simul-
taneously, a decrease in protective bacteria such as Bifidobacteria
and Lactobacilli [24] has also been observed, although Enterobacte-
ria increase [25]. Healthy elderly patients harbor a larger range of
Bacteroides strains [24]. Lifestyle, mainly including diet, plays an
important role in gut composition changes in elderly patients. In
addition, there is evidence that loss of gut microbiota diversity,
although not significantly associated with chronological aging,
can occur in elderly individuals [21]. In conclusion, age is probably
an independent risk factor for developing CDI, but it is sometimes
difficult to determine which of the entangled factors of antibiotics
use, IPP use, and hospital stays which increase concomitantly with
age are predominant [9].Gut microbiota dysbiosis and Clostridium difficile infections
Most studies observed a loss in gut microbiota diversity
[26–30]. In a large cohort, Rea et al. observed lower gut microbiota
diversity in elderly patients with CDI compared to healthy individ-
uals [27], but differences have also been observed between CD
infected patients and CD carriers. Interestingly, while decreased
diversity is comparable in CDI patients and asymptomatic C. diffi-
cile carriers, the microbiome of carriers is structurally more similar
to the microbiome of healthy individuals in comparison to CDI
patients [30]. A lower abundance of Proteobacteria and a higher
abundance of Bifidobacteria has been observed in carriers in com-
parison with the microbiome of patients with CDI [30]. The authors
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and a decrease in Enterococcaceae in patients with CD infections. In
addition, Buffie et al. detected a correlation between the presence
of Clostridium group XIVa in carriers in comparison with CDI sam-
ples [31].
Some authors have compared the gut microbiota of patients
exposed to the same CDI risk factors, some of whom had developed
an infection while others did not. Milani et al. [32] reported a
decrease in butyrate production from Ruminococcaceae and Lach-
nospiraceae, Clostridium clusters IV and XIVa in patients with CDI
or those treated with antibiotics compared to controls by. Vincent
et al. performed a case-control study including individuals exposed
to classic CDI risk factors (hospitalization, antibiotic treatment),
and demonstrated that a decrease in sequences belonging to
Clostridiales Incertae Sedis XI was independently and significantly
associated with CDI development [33]. Milani et al. recently used
metagenomics targeting the 16S rRNA gene using Illumina tech-
nology to compare the gut microbiome of 74 hospitalized elderly
patients, including 25 CDI patients, 29 patients treated with antibi-
otics but who were negative for CD and 30 controls (inpatients not
receiving antibiotics and without CD) [26]. In addition to the well
described decreased diversity in the CDI group, an underrepresen-
tation of commensal bacteria, including Alistipes, Bacteroides, Lach-
nospira and Barnesiella genera, was highlighted as well as an
increase in opportunistic pathogens including Klebsiella and Escher-
ichia/Shigella genera members [26]. Microbiome functionality was
assessed using shotgun metagenomics on a few randomly selected
samples and a focus on Peptostreptococcaceae confirmed these
data. Nevertheless, as is often the case of metagenomic studies,
the high taxonomic level of analysis (order, family or at best gen-
era) in this well-conducted and informative study is regrettable.
Other studies have compared the gut microbiota of patients
with diarrhea caused by CD and diarrhea caused by other patho-
gens. Using metagenomics targeted on 16S rRNA to compare the
gut microbiota of 12 patients with diarrhea caused by CDI and
12 patients with diarrhea with another cause, it has been revealed
that patients without CDI had significantly more species belonging
to Lactobacillaceae, Rikenellaceae, Helicobacteraceae, Provotellaceae,
Ruminococcaceae and Rhodobacteraceae [34]. In a large study
including 338 individuals, Schubert et al. used 454 GS FLX pyrose-
quencing to compare the gut microbiota of 94 patients with CDI, 89
patients with diarrhea caused by a pathogen other than C. difficile
and 155 controls [28]. Firstly, decreased diversity was observed
in samples from diarrheic patients regardless of the cause, com-
pared with non-diarrheal controls [28]. Secondly, several bacterial
species within the Ruminococcaceae, Lachnospiraceae, and Porphy-
romonadaceae families and Bacteroides genera (including Alistipes
and Prevotella spp.) were absent in CDI patients, although these
were strongly associated with non-diarrheal controls. In addition,
Enterococcus species, Enterobacteriaceae, Erysipelotrichaceae and
some Lachnospiraceae were higher in CDI patients [28].
Some studies have longitudinally observed gut microbiota
changes over the course of recurrences. The loss of gut microbiota
diversity appears to progressively worsen with each recurrence
[29]. In addition, as demonstrated in a recent study including 21
controls, 20 patients with primary CDI and 19 patients with recur-
rent CDI, primary bile acids in stool were significantly elevated in
primary CDI patients compared to controls and in recurrent CDI
patients compared to primary CDI patients [35]. Allegretti also
demonstrated that both primary and recurrent CDI stool samples
had significantly fewer Clostridiales and members of the Collinsella
genus compared with controls [35].
Because the morbidity and the mortality associated with CDI
varies dramatically depending on the causative strains [4], differ-
ences in gut microbiota were explored in relation to the Clostridium
difficile ribotypes. One study, performed using denaturing highpressure liquid chromatography (DHPLC) on 208 fecal samples,
compared gut microbiota composition according to the C. difficile
ribotype [36]. Interestingly, in the ribotype O27 group, a ribotype
associated with severe infections, some Bacteroides sp., Enterobac-
teriaceae were decreased and the lack of Bifidobacterium longum
was highly significant [36].
Finally, few studies have explored fungal composition during
CDI. Sangster et al., using ITS primers, demonstrated that fungi
belonging to the Penicillium genus were more frequently associated
with CDI compared to controls, while most of the OTU corre-
sponded to ‘‘uncultured fungi” [34].
Restoration after fecal microbiota transplantation
FMT is associated with the recovery of greater diversity, and
with the reemergence of the dominance of members of the Bac-
teroidetes and Firmicutes phyla, including Clostridium groups and
butyrate-producing bacteria [37,38]. Simultaneously, decreased
levels of Proteobacteria usually follow FMT [39]. Interestingly, func-
tional studies performed using metagenomics have highlighted
significant changes such as a decrease in amino acid transport sys-
tems [39]. The dynamic behavior of gut microbiota after FMT, as
demonstrated by some authors, appears to be close to the range
of normal variation between healthy individuals over time
[40,41]. Weingarden et al. analyzed the gut microbiota of four
patients treated with FMT by high throughput 16S rRNA gene
sequencing. The post-FMT microbiome was initially similar
between recipient and donor samples but the two later diverged
[41]. Finally, the co-existence of gut microbiota in both healthy
donors and recipients may last up to 3 months [42].
Comparing gut flora composition before and after FMT in
patients with recurrent FMT showed that members of the Strepto-
coccaceae, Enterococcaceae, and Enterobacteriaceae families were
significantly increased despite putative butyrate producers such
as Lachnospiraceae and Ruminococcaceae families being signifi-
cantly reduced in patients with recurrent CDI compared with con-
trols and post-FMT patients [40]. Finally, changes in bile acid
composition (particularly deoxycholate and litocholic acid) follow-
ing fecal microbiota transplantation appears to play a key role in
the success of FMT [43].
In addition to these bacterial changes, FMT also transfers
archaea (approximately 108 per gram of stool), viruses (approxi-
mately 108 per gram of stool), fungi (approximately 106 per gram
of stool) and protists. To date, no study has been interested com-
prehensively to these changes [44].
Conclusion and perspectives
In conclusion, most of the studies detected a decreased diversity
in patients developing a CDI before and during infection regardless
of the risk exposure factors [14,27–29]. However, the results of
studies focusing on this topic are frequently heterogeneous and
sometimes contradictory. Most of these studies are performed
using metagenomics, including several biases as previously
described [7]. In addition, unfortunately, as we describe in this
paper and despite recent advances in metagenomics, most studies
look at relationships between gut microbiota and CDI at high phy-
lum level such as phyla, families or, at best, genus level. These
studies remain intellectually interesting, but none of the conclu-
sions can have a potential therapeutic effect.
Nevertheless, there is strong evidence to support the rehabilita-
tion of the gut microbiota of patients suffering from Clostridium
difficile infections because of the dysbiosis observed. Microbiome-
based interventions, in addition to FMT, have demonstrated their
effectiveness over CDI but the ability, acceptability and potentially
the long-term consequences of FMT, as recently suggested by the
14 J.-C. Lagier /Human Microbiome Journal 2 (2016) 10–14transfer of multiple populations of bacteriophages [45], requires
the development of more focused approaches compared with the
entire FMT process. Empirical therapeutic pathways, as previously
reported for SER-109 [46] or the administration of spores of non-
toxigenic Clostridium difficile strain (NTCD-M3) [47], are attractive
options, but lack of knowledge of the specific species to administer
should trigger the design of comprehensive studies coupling both
metagenomics using optimized extraction protocols [48] and cul-
turomics [49], as recently demonstrated for elucidation of the role
of C. butyricum in necrotizing enterocolitis [50]. Such studies could
consequently herald a new innovative and specific therapeutic
outlook.
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